Health
Genethon develops gene therapy for treating Duchenne muscular dystrophy – News-Medical.net
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM,…
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004.
This trial’s goal is to assess the safety and efficacy of an innovative gene therapy designed at Genethon, combining an AAV-type viral vector…
-
Noosa News19 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News22 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General22 hours agoDairy farmers devastated by floods across parts of New South Wales
-
General19 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity